Hari P. Miskin

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells”.

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

Blood Advances(2020)10.1182/bloodadvances.2020001800

N/A

0DataRank · unranked

63 citations

John J. Powers, Alex Achille, Melanie Mediavilla-Varela, Wael Gamal, Karen L. Burger +11 more

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0964

N/A

0DataRank · unranked

13 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596.v1

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia

HemaSphere(2025)10.1002/hem3.70067

N/A

0DataRank · unranked

0 citations

Yue Ren, Svitlana Tyekucheva, Jon Arnason, Adam Boruchov, Caron A. Jacobson +6 more